{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:05:22Z","timestamp":1790301922452,"version":"4.1.0"},"reference-count":65,"publisher":"Portland Press Ltd.","issue":"6","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the brain, aminopeptidase A (APA), a membrane-bound zinc metalloprotease, generates angiotensin III from angiotensin II. Brain angiotensin III exerts a tonic stimulatory effect on the control of blood pressure (BP) in hypertensive rats and increases vasopressin release. Blocking brain angiotensin III formation by the APA inhibitor prodrug RB150\/firibastat normalizes arterial BP in hypertensive deoxycorticosterone acetate (DOCA)-salt rats without inducing angiotensin II accumulation. We therefore hypothesized that another metabolic pathway of brain angiotensin II, such as the conversion of angiotensin II into angiotensin 1-7 (Ang 1-7) by angiotensin-converting enzyme 2 (ACE2) might be activated following brain APA inhibition. We found that the intracerebroventricular (icv) administration of RB150\/firibastat in conscious DOCA-salt rats both inhibited brain APA activity and induced an increase in brain ACE2 activity. Then, we showed that the decreases in BP and vasopressin release resulting from brain APA inhibition with RB150\/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist. Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150\/firibastat treatment, subsequently increasing Ang 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in vasopressin release induced by RB150\/firibastat. RB150\/firibastat treatment constitutes an interesting therapeutic approach to improve BP control in hypertensive patients by inducing in the brain renin\u2013angiotensin system, hyperactivity of the beneficial ACE2\/Ang 1-7\/MasR axis while decreasing that of the deleterious APA\/Ang II\/Ang III\/ATI receptor axis.<\/jats:p>","DOI":"10.1042\/cs20201385","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T14:15:34Z","timestamp":1615212934000},"page":"775-791","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Brain ACE2 activation following brain aminopeptidase A blockade by firibastat in salt-dependent hypertension"],"prefix":"10.1042","volume":"135","author":[{"given":"Reda","family":"Hmazzou","sequence":"first","affiliation":[{"name":"Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris F-75231 France"},{"name":"Center for Interdisciplinary Research in Biology (CIRB), Coll\u00e8ge de France, Paris F-75231 France"},{"name":"Universit\u00e9 Ren\u00e9 Descartes, \u201cEcole doctorale MTCI n\u00b0563\u201d, Paris F-75270, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Marc","sequence":"additional","affiliation":[{"name":"Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris F-75231 France"},{"name":"Center for Interdisciplinary Research in Biology (CIRB), Coll\u00e8ge de France, Paris F-75231 France"},{"name":"Quantum Genomics SA, Paris F-75015, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Flahault","sequence":"additional","affiliation":[{"name":"Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris F-75231 France"},{"name":"Center for Interdisciplinary Research in Biology (CIRB), Coll\u00e8ge de France, Paris F-75231 France"},{"name":"Universit\u00e9 Ren\u00e9 Descartes, \u201cEcole doctorale MTCI n\u00b0563\u201d, Paris F-75270, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4617-4850","authenticated-orcid":false,"given":"Romain","family":"Gerbier","sequence":"additional","affiliation":[{"name":"Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris F-75231 France"},{"name":"Center for Interdisciplinary Research in Biology (CIRB), Coll\u00e8ge de France, Paris F-75231 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"De Mota","sequence":"additional","affiliation":[{"name":"Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris F-75231 France"},{"name":"Center for Interdisciplinary Research in Biology (CIRB), Coll\u00e8ge de France, Paris F-75231 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-0401","authenticated-orcid":false,"given":"Catherine","family":"Llorens-Cortes","sequence":"additional","affiliation":[{"name":"Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris F-75231 France"},{"name":"Center for Interdisciplinary Research in Biology (CIRB), Coll\u00e8ge de France, Paris F-75231 France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"2021113011201222900_B1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.phrs.2017.06.016","article-title":"Brain renin-angiotensin system in the pathophysiology of cardiovascular diseases","volume":"125","author":"Huber","year":"2017","journal-title":"Pharmacol. Res."},{"key":"2021113011201222900_B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pneurobio.2011.07.001","article-title":"Brain renin-angiotensin\u2013a new look at an old system","volume":"95","author":"Wright","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"2021113011201222900_B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0167-0115(95)00084-O","article-title":"Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions","volume":"59","author":"Wright","year":"1995","journal-title":"Regul. Pept."},{"key":"2021113011201222900_B4","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1021\/jm00044a016","article-title":"Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols","volume":"37","author":"Chauvel","year":"1994","journal-title":"J. Med. Chem."},{"key":"2021113011201222900_B5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1021\/jm00085a013","article-title":"Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation","volume":"35","author":"Fourni\u00e9-Zaluski","year":"1992","journal-title":"J. Med. Chem."},{"key":"2021113011201222900_B6","doi-asserted-by":"publisher","first-page":"11968","DOI":"10.1073\/pnas.93.21.11968","article-title":"Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release","volume":"93","author":"Zini","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011201222900_B7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000054439","article-title":"PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III","volume":"69","author":"Reaux","year":"1999","journal-title":"Neuroendocrinology"},{"key":"2021113011201222900_B8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/00001756-199803300-00011","article-title":"Inhibition of vasopressinergic neurons by central injection of a specific aminopeptidase A inhibitor","volume":"9","author":"Zini","year":"1998","journal-title":"Neuroreport"},{"key":"2021113011201222900_B9","doi-asserted-by":"publisher","first-page":"13415","DOI":"10.1073\/pnas.96.23.13415","article-title":"Aminopeptidase A inhibitors as potential central antihypertensive agents","volume":"96","author":"Reaux","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011201222900_B10","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1073\/pnas.0402312101","article-title":"Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension","volume":"101","author":"Fournie-Zaluski","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011201222900_B11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1126\/science.6879184","article-title":"Angiotensin synthesis in the brain and increased turnover in hypertensive rats","volume":"221","author":"Ganten","year":"1983","journal-title":"Science"},{"key":"2021113011201222900_B12","doi-asserted-by":"publisher","first-page":"II","DOI":"10.1161\/01.HYP.3.6_Pt_2.II-14","article-title":"Renin-like activity in the rat brain during the development of DOC-salt hypertension","volume":"3","author":"Basso","year":"1981","journal-title":"Hypertension"},{"key":"2021113011201222900_B13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/HYPERTENSIONAHA.107.098772","article-title":"Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension","volume":"51","author":"Bodineau","year":"2008","journal-title":"Hypertension"},{"key":"2021113011201222900_B14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.119.12675","article-title":"Evolution of a new class of antihypertensive drugs: targeting the brain renin-angiotensin system","volume":"75","author":"Llorens-Cortes","year":"2020","journal-title":"Hypertension"},{"key":"2021113011201222900_B15","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002092","article-title":"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension","author":"Azizi","year":"2019","journal-title":"J. Hypertens."},{"key":"2021113011201222900_B16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.119.040070","article-title":"Efficacy and safety of firibastat, a first-in-class brain aminopeptidase A inhibitor, in hypertensive overweight patients of multiple ethnic origins","volume":"140","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"2021113011201222900_B17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00041552-200503000-00011","article-title":"The renin-angiotensin system: peptides and enzymes beyond angiotensin II","volume":"14","author":"Reudelhuber","year":"2005","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"2021113011201222900_B18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/HYPERTENSIONAHA.106.076216","article-title":"Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?","volume":"50","author":"Chappell","year":"2007","journal-title":"Hypertension"},{"key":"2021113011201222900_B19","doi-asserted-by":"publisher","first-page":"H393","DOI":"10.1152\/ajpheart.00075.2012","article-title":"Chronic infusion of angiotensin-(1-7) into the lateral ventricle of the brain attenuates hypertension in DOCA-salt rats","volume":"303","author":"Guimaraes","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011201222900_B20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.lfs.2013.08.020","article-title":"Angiotensin (1-7) contributes to nitric oxide tonic inhibition of vasopressin release during hemorrhagic shock in acute ethanol intoxicated rodents","volume":"93","author":"Whitaker","year":"2013","journal-title":"Life Sci."},{"key":"2021113011201222900_B21","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1161\/HYPERTENSIONAHA.107.108944","article-title":"Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents","volume":"51","author":"Hern\u00e1ndez Prada","year":"2008","journal-title":"Hypertension"},{"key":"2021113011201222900_B22","doi-asserted-by":"publisher","first-page":"H1057","DOI":"10.1152\/ajpheart.00433.2013","article-title":"Activation of angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/Mas axis attenuates the cardiac reactivity to acute emotional stress","volume":"305","author":"Lima","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011201222900_B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2174\/0929866522666151013130550","article-title":"Anti-hypertensive effects of diminazene aceturate: an angiotensin- converting enzyme 2 activator in rats","volume":"23","author":"De Maria","year":"2016","journal-title":"Protein Pept. Lett."},{"key":"2021113011201222900_B24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/HYPERTENSIONAHA.113.02856","article-title":"Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro","volume":"63","author":"Haber","year":"2014","journal-title":"Hypertension"},{"key":"2021113011201222900_B25","doi-asserted-by":"publisher","first-page":"H261","DOI":"10.1152\/ajpheart.1986.251.2.H261","article-title":"Central renin-angiotensin system and the pathogenesis of DOCA-salt hypertension in rats","volume":"251","author":"Itaya","year":"1986","journal-title":"Am. J. Physiol."},{"key":"2021113011201222900_B26","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1021\/jm00035a014","article-title":"Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors","volume":"37","author":"Chauvel","year":"1994","journal-title":"J. Med. Chem."},{"key":"2021113011201222900_B27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0306-4522(96)00660-4","article-title":"Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats","volume":"78","author":"Zini","year":"1997","journal-title":"Neuroscience"},{"key":"2021113011201222900_B28","doi-asserted-by":"publisher","first-page":"R1293","DOI":"10.1152\/ajpregu.00339.2011","article-title":"Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays","volume":"301","author":"Pedersen","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2021113011201222900_B29","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1161\/HYPERTENSIONAHA.112.198622","article-title":"Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2","volume":"60","author":"Ye","year":"2012","journal-title":"Hypertension"},{"key":"2021113011201222900_B30","volume-title":"The Rat Brain in Stereotaxic Coordinates [En ligne]","author":"Paxinos","year":"1986","edition":"2nd"},{"key":"2021113011201222900_B31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1476-5381.1957.tb01354.x","article-title":"Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse","volume":"12","author":"Haley","year":"1957","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"2021113011201222900_B32","doi-asserted-by":"publisher","first-page":"11852","DOI":"10.1021\/ja0277226","article-title":"Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors","volume":"124","author":"Dales","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"2021113011201222900_B33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0361-9230(94)90104-X","article-title":"Characterization of a new angiotensin antagonist selective for angiotensin-(1\u20137): evidence that the actions of angiotensin-(1\u20137) are mediated by specific angiotensin receptors","volume":"35","author":"Santos","year":"1994","journal-title":"Brain Res. Bull."},{"key":"2021113011201222900_B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0165-0270(90)90040-M","article-title":"Microdialysis measurement of in vivo neuropeptide release","volume":"34","author":"Kendrick","year":"1990","journal-title":"J. Neurosci. Methods"},{"key":"2021113011201222900_B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0006-8993(94)91215-7","article-title":"Release of angiotensin in the paraventricular nucleus in response to hyperosmotic stimulation in conscious rats: a microdialysis study","volume":"637","author":"Qadri","year":"1994","journal-title":"Brain Res."},{"key":"2021113011201222900_B36","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/jssc.200700159","article-title":"Nano-LC-MS\/MS for the monitoring of angiotensin IV in rat brain microdialysates: limitations and possibilities","volume":"30","author":"Lanckmans","year":"2007","journal-title":"J. Sep. Sci."},{"key":"2021113011201222900_B37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrn1902","article-title":"The sympathetic control of blood pressure","volume":"7","author":"Guyenet","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"2021113011201222900_B38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/sj.bjp.0705262","article-title":"Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives","volume":"139","author":"Veerasingham","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"2021113011201222900_B39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.112.190942","article-title":"Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats","volume":"60","author":"Marc","year":"2012","journal-title":"Hypertension"},{"key":"2021113011201222900_B40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1161\/HYPERTENSIONAHA.108.123844","article-title":"Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice","volume":"53","author":"Xia","year":"2009","journal-title":"Hypertension"},{"key":"2021113011201222900_B41","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/01.HYP.0000259942.38108.20","article-title":"Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats","volume":"49","author":"Yamazato","year":"2007","journal-title":"Hypertension"},{"key":"2021113011201222900_B42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"2021113011201222900_B43","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/CIRCRESAHA.113.301811","article-title":"Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension","volume":"113","author":"Xia","year":"2013","journal-title":"Circ. Res."},{"key":"2021113011201222900_B44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1161\/HYPERTENSIONAHA.114.04691","article-title":"Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation","volume":"65","author":"Sriramula","year":"2015","journal-title":"Hypertension"},{"key":"2021113011201222900_B45","doi-asserted-by":"publisher","first-page":"R370","DOI":"10.1152\/ajpregu.00366.2014","article-title":"Brain ACE2 overexpression reduces DOCA-salt hypertension independently of endoplasmic reticulum stress","volume":"308","author":"Xia","year":"2015","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2021113011201222900_B46","doi-asserted-by":"publisher","first-page":"C1073","DOI":"10.1152\/ajpcell.00364.2012","article-title":"Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1\/2 signaling","volume":"304","author":"Xiao","year":"2013","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021113011201222900_B47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/351233a0","article-title":"Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor","volume":"351","author":"Murphy","year":"1991","journal-title":"Nature"},{"key":"2021113011201222900_B48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0006-291X(05)80983-0","article-title":"Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome","volume":"185","author":"Sasamura","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011201222900_B49","doi-asserted-by":"publisher","first-page":"9455","DOI":"10.1016\/S0021-9258(19)50109-0","article-title":"Cloning and expression of a novel angiotensin II receptor subtype","volume":"267","author":"Sandberg","year":"1992","journal-title":"J. Biol. Chem."},{"key":"2021113011201222900_B50","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1152\/ajprenal.1992.262.1.F17","article-title":"Release of angiotensins in paraventricular nucleus of rat in response to physiological and chemical stimuli","volume":"262","author":"Harding","year":"1992","journal-title":"Am. J. Physiol."},{"key":"2021113011201222900_B51","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/00004872-198808000-00002","article-title":"Brain angiotensin in the developing spontaneously hypertensive rat","volume":"6","author":"Phillips","year":"1988","journal-title":"J. Hypertens."},{"key":"2021113011201222900_B52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11906-017-0731-4","article-title":"DOCA-salt hypertension: an update","volume":"19","author":"Basting","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"key":"2021113011201222900_B53","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1016\/S0021-9258(17)34557-X","article-title":"Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney","volume":"253","author":"Odya","year":"1978","journal-title":"J. Biol. Chem."},{"key":"2021113011201222900_B54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","article-title":"Ang II (Angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent","volume":"75","author":"Serfozo","year":"2020","journal-title":"Hypertension"},{"key":"2021113011201222900_B55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.regpep.2007.03.006","article-title":"Enzymatic pathways of the brain renin\u2013angiotensin system: Unsolved problems and continuing challenges","volume":"143","author":"Karamyan","year":"2007","journal-title":"Regul. Pept."},{"key":"2021113011201222900_B56","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system","volume":"112","author":"Lautner","year":"2013","journal-title":"Circ. Res."},{"key":"2021113011201222900_B57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.peptides.2017.09.005","article-title":"Hypotensive effect induced by microinjection of Alamandine, a derivative of angiotensin-(1-7), into caudal ventrolateral medulla of 2K1C hypertensive rats","volume":"96","author":"Soares","year":"2017","journal-title":"Peptides"},{"key":"2021113011201222900_B58","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1096\/fj.201600784R","article-title":"Development of original metabolically stable apelin-17 analogs with diuretic and cardiovascular effects","volume":"31","author":"Gerbier","year":"2017","journal-title":"FASEB J."},{"key":"2021113011201222900_B59","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.110.167346","article-title":"An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats","volume":"57","author":"Marques","year":"2011","journal-title":"Hypertension"},{"key":"2021113011201222900_B60","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"2021113011201222900_B61","doi-asserted-by":"publisher","first-page":"108132","DOI":"10.1016\/j.diabres.2020.108132","article-title":"COVID-19, diabetes mellitus and ACE2: the conundrum","volume":"162","author":"Pal","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2021113011201222900_B62","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.110.955369","article-title":"Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction","volume":"122","author":"Zhong","year":"2010","journal-title":"Circulation"},{"key":"2021113011201222900_B63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"2021113011201222900_B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"2021113011201222900_B65","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/jmv.25728","article-title":"The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/6\/775\/905902\/cs-2020-1385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/6\/775\/905902\/cs-2020-1385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:17:31Z","timestamp":1638274651000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/135\/6\/775\/228040\/Brain-ACE2-activation-following-brain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,26]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20201385","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,3]]}}}